Sarah K Tasian, MD

faculty photo
Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
Children's Hospital of Philadelphia
Division of Oncology
Hematologic Malignancies section
3501 Civic Center Boulevard, CTRB 3010
Philadelphia, PA 19104
Education:
BS, BA (Biological Sciences, Psychology)
University of Notre Dame, 1999.
MD (Medicine)
Baylor College of Medicine, 2004.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

I have clinical expertise in the care of children, adolescents, and young adults with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and juvenile myelomonocytic leukemia (JMML). My particular clinical interests include integration of comprehensive leukemia genetic data with therapy selection for children with high risk newly-diagnosed and relapsed ALL and AML with a focus on precision medicine treatment approaches.

I attend on the Hematologic Malignancies inpatient service and outpatient Oncology clinic at the Children's Hospital of Philadelphia. I have procedural expertise in bone marrow aspiration and biopsy, lumbar punctures (spinal taps), Ommaya reservoir taps, administration of intrathecal chemotherapy, and skin biopsies.

Description of Other Expertise

I am a primary clinical mentor in Hematologic Malignancies for first, second, and third year pediatric hematology-oncology fellows and supervise their patient care in the inpatient and outpatient clinical settings. I also teach and supervise pediatric residents in the inpatient setting.

Description of Research Expertise

My career goal as an academic physician-scientist is to develop molecularly-targeted therapies for children with high-risk leukemias to prevent relapse, improve survival, and minimize toxicities.

My independent translational research program focuses upon novel therapeutics for high-risk pediatric leukemias via:
(1) Characterization of signal transduction networks and preclinical testing of kinase inhibitors for subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
(2) Preclinical testing of leukemia antigen-redirected chimeric antigen receptor (CAR) T cell immunotherapy for childhood AML and ALL
(3) Early phase clinical trial testing of targeted therapies for children with leukemia through the Children’s Oncology Group (COG) and other consortia

Successful integration of our bench-based and clinical studies has led to several trials testing new therapies in children with high-risk leukemias. I have leadership roles in the COG ALL, Myeloid Diseases, and AML New Agents steering committees and am the COG Developmental Therapeutics Committee Vice Chair of Biology for Hematologic Malignancies. I also chair the COG phase 2 clinical trial AALL1521 (ruxolitinib/chemotherapy for children with CRLF2/JAK pathway-mutant Ph-like ALL), co-lead development of immunotherapy trials for children with relapsed AML, and am PI of the CHOP Center for Childhood for Cancer Research leukemia biorepository.

Current Tasian laboratory members and collaborators:
Asen Bagashev, PhD (research associate/scientist)
John Chukinas, BS (research technician)
Yang Ding, MD (post-doctoral fellow/instructor)
David Hottman Allen, PhD (post-doctoral fellow)
Christian Hurtz, PhD (research associate/scientist)
JP Loftus, BS (research technician)
Lisa Niswander, MD PhD (post-doctoral fellow)
Sisi Zheng, MD (post-doctoral fellow)

Selected Publications

Pearson ADJ, Zwaan CM, Kolb EA, Karres D, Guillot J, Kim SY, Marshall L, Tasian SK, Smith M, Cooper T, Adamson PC, Barry E, Benettaib B, Binlich F, Borgman A, Brivio E, Capdeville R, Delgado D, Faller DV, Fogelstrand L, Goodman Fraenkel P, Hasle H, Heenen D, Kaspers G, Kieran M, Klusmann J-H, Lesa G, Ligas F, Mappa S, Mohamed H, Moore A, Morris J, Nottage K, Reinhardt D, Scobie N, Simko S, Winkler T, Norga K, Reaman G, Vassal G.: Paediatric Strategy Forum for Medicinal Product Development for Acute Myeloid Leukaemia In Children and Adolescents: ACCELERATE in Collaboration with the European Medicines Agency with Participation of the Food and Drug Administration. European Journal of Cancer 136: 116-129, September 2020 Notes: https://www.sciencedirect.com/science/article/abs/pii/S0959804920302422.

Contreras C, Higham C, Behert A, Kim K, Stieglitz E, Tasian SK: Clinical Utilization of Blinatumomab and Inotuzumab Immunotherapy in Children with Relapsed or Refractory B-Acute Lymphoblastic Leukemia. Pediatric Blood and Cancer September 2020 Notes: Accepted.

He B, Gao P, Ding YY, Chen C-H, Chen G, Chen C, Kim H, Tasian SK, Hunger SP, Tan K. Science Advances: Diverse Non-Coding Mutations Contribute to Deregulation of Cis-Regulatory Landscape in Pediatric Cancers. Science Advances Page: in press, July 2020.

Tasian SK: Invited expert interview. VJHemOnc June 2020 Notes: https://www.vjhemonc.com/video/lzxq09qmkhe-diagnostic-strategies-for-ph-like-all/

Vadakeklolathu J, Minden MD, Hood T, Church SE, Reeder S, Altmann H, Sullivan AM, Viboch E, Patel T, Ibramimova N, Warren SE, Arruda A, Liang Y, Schmitz M, Cesano A, Valk PJM, Löwenberg B, Pockley AG, Bornhäuser M, Tasian SK, Rettig MP, Davidson-Moncada J, DiPersio JF, Rutella S: Immune Landscapes Predict Chemotherapy Resistance and Immunotherapy Response in Acute Myeloid Leukemia. Science Translational Medicine 12(546): eaaz0463. June 2020 Notes: doi: 10.1126/scitranslmed.aaz0463.

Tasian SK: Invited expert interview. VJHemOnc June 2020 Notes: https://www.vjhemonc.com/video/qvom6li5juy-immunotherapy-for-pediatric-aml/

Ross S, Bagashev A, Schneider D, Dropulic B, Hu P, Tasian SK*, Fry TJ* : Multi-antigen targeting of CD19, CD22, and TSLPR to prevent Ph-like ALL resistance. AACR annual meeting (San Diego, CA) June 2020 Notes: *co-senior authors poster presentation by a mentee; meeting held virtually due to viral pandemic

Tasian SK: Invited expert interview. VJHemOnc June 2020 Notes: https://www.vjhemonc.com/video/zgkpanht-0-targeted-therapy-for-ph-like-all/

Zhao X, Li MM, Schubert J, Wu J, Lin F, Wertheim GB, Surrey L, Luo M, Zhong Y, Wu C, Cao K, Aplenc R, Bagatell R, Mosse YP, Olson TS, Santi M, Tasian SK, Storm P, Maris JM, Hunger S: Clinical Significance of Serial Tumor Next Generation Sequencing (NGS) in 155 Pediatric Cancer Patients. J Clin Oncol Page: abstract #306513, June 2020 Notes: Poster presentation at ASCO annual meeting (Chicago, IL) given by collaborator; virtual meeting due to viral pandemic.

Rheingold SR, Silverman LB, Whitlock JA, Sposto R, Schafer ES, Schultz KR, Hutchinson RJ, Gaynon PG, Bateman C, Cooper TM, Laetsch TW, Sulis ML, Wayne AL, Tasian SK: Temsirolimus combined with etoposide and cyclophosphamide for relapsed/refractory acute lymphoblastic leukemia: Therapeutic advances in Childhood Leukemia Consortium (TACL 2014-001) trial. J Clin Oncol June 2020 Notes: Oral presentation at ASCO annual meeting (Chicago, IL) given by collaborator; virtual meeting due to viral pandemic.

back to top
Last updated: 09/08/2020
The Trustees of the University of Pennsylvania